Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Lyles
Alan
A
D000081:Acetamides / Q000191:economics* / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003428:Cross Infection / Q000188:drug therapy / Q000191:economics; D030881:Disclosure; D006801:Humans; D000069349:Linezolid; D016106:Methicillin Resistance; D023303:Oxazolidinones / Q000191:economics* / Q000627:therapeutic use; D017712:Peer Review, Research / Q000379:methods*; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy / Q000191:economics; D012107:Research Design; D013211:Staphylococcus aureus / Q000187:drug effects; D014640:Vancomycin / Q000191:economics* / Q000627:therapeutic use
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D014640:Vancomycin; D000069349:Linezolid